恒瑞医药(01276)：国家药监局核准签发关于 HRS-7172 片的《药物临床试验批准通知书》

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of HRS-7172 tablets, a new anti-tumor small molecule inhibitor developed by the company, with no similar drugs approved for market domestically or internationally [1] Group 1 - The company has announced the initiation of clinical trials for HRS-7172 tablets [1] - HRS-7172 tablets represent the company's independent research and development efforts in the field of oncology [1] - The total research and development investment for the HRS-7172 project has reached approximately 28.41 million yuan [1]